Micro cap T2 Biosystems has not yet reached cash flow break even
T2 Biosystems Inc. is offering “highly differentiated” products in the fight against sepsis, according to CEO John Sperzel.
“We have the first and only FDA-cleared products able to detect sepsis-causing pathogens directly from whole blood in just three to five hours,” he said, during a presentation at the Sidoti Micro Cap Conference Wednesday. “We’re standing alone as the only company able to detect these sepsis-causing pathogens directly from blood, in a few hours, versus a few days.”
“We…